## STATE OF NEW YORK

3642

2021-2022 Regular Sessions

## IN ASSEMBLY

January 28, 2021

Introduced by M. of A. L. ROSENTHAL -- read once and referred to the Committee on Health

AN ACT in relation to determining whether the state can claim federal financial participation for coverage of and payment for certain prescription digital therapeutics

## The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Legislative finding and declaration. New Yorkers in recov-2 ery for substance and opioid use disorders and in treatment for mental health conditions are losing access to in-person treatment under the state's "stay at home" and social distancing orders as part of coronavirus pandemic mitigation efforts. In recent news reports, experts warn that the coronavirus pandemic may be "a national relapse trigger" for individuals in treatment for alcohol, cocaine, methamphetamine, marijuana, and heroin addiction. Prescription Digital Therapeutics (PDTs) are 9 software-based disease treatments designed to directly treat 10 disease, tested for safety and efficacy in randomized clinical trials, 11 evaluated by the FDA, and prescribed by healthcare providers. These 12 therapies are designed and tested much like traditional prescription 13 drugs with one distinction: rather than swallowing a pill or taking an 14 injection, patients are treated with software. Certain PDTs provide 15 clinicians and patients with evidence-based remote treatment modalities 16 to treat substance and opioid use disorders, mental health, and other diseases and conditions. However, there is no clear statutory benefit 17 category to allow Medicaid coverage for PDTs. In light of the promise of 18 19 PDTs for the treatment of patients with substance use and opioid use 20 disorders during the coronavirus pandemic, this legislation would 21 require that the New York state department of health seek guidance from 22 the Centers for Medicare and Medicaid Services relative to a coverage 23 and reimbursement pathway for PDTs, in order to accelerate access to 24 such therapies for enrollees.

LBD01006-01-1

A. 3642 2

1 § 2. No later than 30 days from the effective date of this section, 2 the New York state department of health shall request guidance from the 3 Centers for Medicare and Medicaid Services to determine whether the 4 state can claim federal financial participation for coverage of and 5 payment for certain prescription digital therapeutics approved by the 6 food and drug administration to treat substance use and opioid use 7 disorders.

§ 3. This act shall take effect immediately.